We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

77 hedge funds and large institutions have $369M invested in Entrada Therapeutics in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 3

24% more funds holding

Funds holding: 62 → 77 (+15)

1.44% less ownership

Funds ownership: 78.91% → 77.46% (-1.4%)

7% less capital invested

Capital invested by funds: $397M → $369M (-$28.6M)

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
77
Holders Change
+15
Holders Change %
+24.19%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
18
Increased
19
Reduced
23
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
American Century Companies
American Century Companies
Missouri
+$1.81M
2
Citadel Advisors
Citadel Advisors
Florida
+$985K
3
Citigroup
Citigroup
New York
+$752K
4
Marshall Wace
Marshall Wace
United Kingdom
+$731K
5
Millennium Management
Millennium Management
New York
+$678K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.62M
3
7IH
72 Investment Holdings
Connecticut
-$2.6M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$678K
5
N
Nuveen
North Carolina
-$330K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$68.9M – – –
MAM
2
MPM Asset Management
Massachusetts
$62.7M – – –
5VM
3
5AM Venture Management
California
$62.5M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$39M -$3.62M -256,316 -9%
BlackRock
5
BlackRock
New York
$21.1M -$231K -16,369 -1%
RG
6
Redmile Group
California
$18.2M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$15.3M +$194K +13,742 +1%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$14.6M -$296K -20,940 -2%
SG
9
StepStone Group
California
$10.8M – – –
TCM
10
TCG Crossover Management
California
$8.29M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$6.74M +$226K +15,977 +3%
State Street
12
State Street
Massachusetts
$6.17M +$107K +7,558 +2%
American Century Companies
13
American Century Companies
Missouri
$5.19M +$1.81M +127,703 +54%
Northern Trust
14
Northern Trust
Illinois
$2.82M -$19K -1,346 -0.7%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$2.38M -$5.2M -367,602 -69%
Charles Schwab
16
Charles Schwab
California
$2.22M +$74.5K +5,271 +3%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.57M -$63.1K -4,462 -4%
Morgan Stanley
18
Morgan Stanley
New York
$1.52M +$127K +8,954 +9%
MCM
19
Moore Capital Management
New York
$1.49M – – –
AACP
20
Advantage Alpha Capital Partners
California
$1.29M -$198K -14,021 -13%
Millennium Management
21
Millennium Management
New York
$1.02M +$678K +47,979 +200%
TD Asset Management
22
TD Asset Management
Ontario, Canada
$1.01M -$678K -47,946 -40%
Citadel Advisors
23
Citadel Advisors
Florida
$987K +$985K +69,676 New
N
24
Nuveen
North Carolina
$810K -$330K -23,373 -29%
Citigroup
25
Citigroup
New York
$798K +$752K +53,177 +1,710%
1
2 3 4

TRDA Hedge Fund Activity: Q1 2024 in Review

77 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2024, worth a combined $369M — down 7.2% from $397M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new TRDA positions and 3 closed out — a net gain of 15 holders — while 19 added to existing stakes and 23 trimmed.

The largest buyer was American Century Companies, adding an estimated $1.81M. The largest seller was Fidelity Investments, cutting an estimated $5.2M.

  • 77 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2024, up from 62 in Q4 2023.
  • Funds reported $369M of Entrada Therapeutics stock for Q1 2024, down 7.2% quarter-over-quarter.
  • 18 funds opened new Entrada Therapeutics positions in Q1 2024 and 3 closed out, a net change of +15 holders.
  • The largest Entrada Therapeutics buyer in Q1 2024 was American Century Companies, an estimated $1.81M added.
  • The largest Entrada Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $5.2M sold.

Based on aggregated 13F filings for Q1 2024.